Vanguard Group Inc Cue Biopharma, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,031,421 shares of CUE stock, worth $3.55 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,031,421
Previous 2,283,362
11.03%
Holding current value
$3.55 Million
Previous $4.32 Million
41.65%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CUE
# of Institutions
69Shares Held
13.9MCall Options Held
56.1KPut Options Held
11.1K-
Bleichroeder LP New York, NY2.86MShares$5.01 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$4.2 Million0.06% of portfolio
-
Black Rock Inc. New York, NY757KShares$1.32 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny494KShares$864,4770.0% of portfolio
-
Geode Capital Management, LLC Boston, MA492KShares$861,7980.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $61.9M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...